226 related articles for article (PubMed ID: 1389950)
1. Inhibitors of imipramine metabolism by human liver microsomes.
Skjelbo E; Brøsen K
Br J Clin Pharmacol; 1992 Sep; 34(3):256-61. PubMed ID: 1389950
[TBL] [Abstract][Full Text] [Related]
2. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
Ball SE; Ahern D; Scatina J; Kao J
Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
[TBL] [Abstract][Full Text] [Related]
3. The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors.
Belpaire FM; Wijnant P; Temmerman A; Rasmussen BB; Brøsen K
Eur J Clin Pharmacol; 1998 May; 54(3):261-4. PubMed ID: 9681670
[TBL] [Abstract][Full Text] [Related]
4. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.
Crewe HK; Lennard MS; Tucker GT; Woods FR; Haddock RE
Br J Clin Pharmacol; 1992 Sep; 34(3):262-5. PubMed ID: 1389951
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants.
von Moltke LL; Greenblatt DJ; Court MH; Duan SX; Harmatz JS; Shader RI
J Clin Psychopharmacol; 1995 Apr; 15(2):125-31. PubMed ID: 7782485
[TBL] [Abstract][Full Text] [Related]
6. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.
Jeppesen U; Gram LF; Vistisen K; Loft S; Poulsen HE; Brøsen K
Eur J Clin Pharmacol; 1996; 51(1):73-8. PubMed ID: 8880055
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes.
Hemeryck A; De Vriendt C; Belpaire FM
Eur J Clin Pharmacol; 1999 Feb; 54(12):947-51. PubMed ID: 10192756
[TBL] [Abstract][Full Text] [Related]
8. Fluvoxamine is a potent inhibitor of cytochrome P4501A2.
Brøsen K; Skjelbo E; Rasmussen BB; Poulsen HE; Loft S
Biochem Pharmacol; 1993 Mar; 45(6):1211-4. PubMed ID: 8466541
[TBL] [Abstract][Full Text] [Related]
9. Effect of selective serotonin reuptake inhibitors on the oxidative metabolism of propafenone: in vitro studies using human liver microsomes.
Hemeryck A; De Vriendt C; Belpaire FM
J Clin Psychopharmacol; 2000 Aug; 20(4):428-34. PubMed ID: 10917404
[TBL] [Abstract][Full Text] [Related]
10. The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4'-hydroxylase activity in human liver microsomes.
Kobayashi K; Yamamoto T; Chiba K; Tani M; Ishizaki T; Kuroiwa Y
Br J Clin Pharmacol; 1995 Nov; 40(5):481-5. PubMed ID: 8703653
[TBL] [Abstract][Full Text] [Related]
11. Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro.
Rasmussen BB; Nielsen TL; Brøsen K
Eur J Clin Pharmacol; 1998; 54(9-10):735-40. PubMed ID: 9923577
[TBL] [Abstract][Full Text] [Related]
12. The role of S-mephenytoin 4'-hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation.
Chiba K; Saitoh A; Koyama E; Tani M; Hayashi M; Ishizaki T
Br J Clin Pharmacol; 1994 Mar; 37(3):237-42. PubMed ID: 8198931
[TBL] [Abstract][Full Text] [Related]
13. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine.
Rasmussen BB; Maënpää J; Pelkonen O; Loft S; Poulsen HE; Lykkesfeldt J; Brøsen K
Br J Clin Pharmacol; 1995 Feb; 39(2):151-9. PubMed ID: 7742153
[TBL] [Abstract][Full Text] [Related]
14. N-demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors.
Schmider J; Greenblatt DJ; von Moltke LL; Harmatz JS; Shader RI
J Pharmacol Exp Ther; 1995 Nov; 275(2):592-7. PubMed ID: 7473143
[TBL] [Abstract][Full Text] [Related]
15. Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine.
Brøsen K; Zeugin T; Meyer UA
Clin Pharmacol Ther; 1991 Jun; 49(6):609-17. PubMed ID: 2060250
[TBL] [Abstract][Full Text] [Related]
16. O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants.
Fogelman SM; Schmider J; Venkatakrishnan K; von Moltke LL; Harmatz JS; Shader RI; Greenblatt DJ
Neuropsychopharmacology; 1999 May; 20(5):480-90. PubMed ID: 10192828
[TBL] [Abstract][Full Text] [Related]
17. Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs.
Koyama E; Chiba K; Tani M; Ishizaki T
J Pharmacol Exp Ther; 1997 Jun; 281(3):1199-210. PubMed ID: 9190854
[TBL] [Abstract][Full Text] [Related]
18. The pharmacogenetics of the selective serotonin reuptake inhibitors.
Brøsen K
Clin Investig; 1993 Dec; 71(12):1002-9. PubMed ID: 8124052
[TBL] [Abstract][Full Text] [Related]
19. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.
Ereshefsky L; Riesenman C; Lam YW
Clin Pharmacokinet; 1995; 29 Suppl 1():10-8; discussion 18-9. PubMed ID: 8846618
[TBL] [Abstract][Full Text] [Related]
20. Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs.
Venkatakrishnan K; von Moltke LL; Greenblatt DJ
J Clin Pharmacol; 1999 Jun; 39(6):567-77. PubMed ID: 10354960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
